Physician profile
Gregory A Masters
NPI 1508834680
$1,113.07
in general payments reported to CMS, 2019-2025
30 companies · $146 in 2025
The $146 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $43.21 · 2020: $53.73 · 2021: $259 · 2022: $201 · 2023: $147 · 2024: $264 · 2025: $146.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $557.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $556.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $203.54 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $108.95 | 2020-2024 | Enhertu, Tagrisso |
| Novartis Pharmaceuticals Corporation | $106.10 | 2022-2025 | |
| Incyte Corporation | $70.68 | 2022-2025 | Jakafi |
| Celgene Corporation | $67.04 | 2024-2025 | Reblozyl |
| Pfizer INC. | $53.47 | 2023-2025 | |
| Gilead Sciences, INC. | $50.71 | 2021-2023 | Trodelvy |
| Spectrum Pharmaceuticals INC. | $34.61 | 2023 | Rolvedon |
| Merck Sharp & Dohme LLC | $34.40 | 2021-2022 | |
| Genentech USA, INC. | $33.94 | 2019-2024 | Gazyva, Columvi, Venclexta |
| Bioventus LLC | $32.14 | 2024 | Sonastar |
| Janssen Biotech, INC. | $30.07 | 2019 | |
| Adaptive Biotechnologies Corporation | $26.74 | 2025 | Clonoseq |
| Blueprint Medicines Corporation | $21.20 | 2024 | Ayvakit |
| Springworks Therapeutics, INC. | $19.38 | 2024 | Ogsiveo |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Karyopharm Therapeutics INC. | $18.74 | 2022 | |
| Pharmacosmos Therapeutics INC. | $18.22 | 2021 | |
| Eisai INC. | $18.09 | 2022 | |
| Deciphera Pharmaceuticals INC. | $17.69 | 2022 | |
| Beigene USA, INC. | $17.45 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.31 | 2024 | Iclusig |
| Mirati Therapeutics, INC. | $16.29 | 2023 | Krazati |
| Genzyme Corporation | $16.28 | 2023 | |
| Aveo Pharmaceuticals, INC. | $15.09 | 2024 | |
| Morphosys, US INC. | $14.47 | 2022 | |
| Array Biopharma INC | $14.46 | 2024 | Mektovi, Braftovi, Tukysa |
| Daiichi Sankyo INC. | $13.33 | 2022 | |
| Seagen INC. | $11.99 | 2021 | |
| Puma Biotechnology, INC. | $11.69 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Masters listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.